As described in note 1, effective January 1, 2026, we revised our internal operating model and reportable segment structure. As a result of this reorganization, the composition of our reporting units for purposes of goodwill impairment testing also changed. Our reporting units are now Life Sciences & Specialty

Solutions, NuSil, VWR Distribution, and VWR Services. These reporting units comprise our Bioscience & Medtech Products and VWR Distribution & Services reportable segments.

In connection with this change, goodwill was reassigned to the revised reporting units as of January 1, 2026 using a relative fair value allocation approach. In accordance with our accounting policy, we evaluated goodwill for impairment immediately before and after the reassignment. No goodwill impairment was identified as a result of the reorganization, and the total carrying value of goodwill was unchanged.


(in millions)	Bioscience & Medtech Products		VWR Distribution & Services		Total
Goodwill, gross	$	2,123.8	$	3,686.9	$	5,810.7
Accumulated impairment losses	$	(19.2)	$	(804.6)	(823.8)
Goodwill, net	$	2,104.6	$	2,882.3	$	4,986.9

Total goodwill did not change as a result of the January 1, 2026 reorganization. The only change in the carrying amount of goodwill during the six months ended June 30, 2026 relates to the effects of foreign currency translation.

We review goodwill for impairment annually on October 1, or more frequently if events or changes in circumstances indicate that goodwill may be impaired.

During the quarter ended March 31, 2026, we observed a sustained decline in our publicly quoted share price and market capitalization, which constituted a triggering event. Accordingly, management performed an interim goodwill impairment assessment for all of our reporting units.

We estimated the fair value of reporting units using a weighted average of two valuation methods based on a discounted cash flows method and a guideline public company method. These valuation methods required management to make various assumptions, including, but not limited to, future profitability, cash flows, revenues, gross margin, SG&A expenses, capital expenditures, investments in debt-free net working capital, discount rates, the weighting of valuation methods and the selection of comparable publicly traded companies. Changes in these assumptions could have resulted in materially different estimates of fair value.

During the quarter ended June 30, 2026, we evaluated whether any events or changes in circumstances had occurred that would indicate that the carrying value of goodwill may not be recoverable. Based on this assessment, no triggering events or impairment indicators were identified, and accordingly, no interim goodwill impairment assessment was required during the quarter.

We will continue to monitor internal and external factors, including trends in our share price and market capitalization, macroeconomic conditions, and operating performance. If market conditions deteriorate further, including continued declines in market capitalization or reductions to financial projections for the VWR Distribution reporting unit, a material non‑cash goodwill impairment charge could be required in a future reporting period.

The following table presents the components of other intangible assets:


(in millions)	June 30, 2026						December 31, 2025
	Gross value		Accumulated amortization and impairment1		Carrying value		Gross value		Accumulated amortization and impairment1		Carrying value
Customer relationships	$	4,864.4	$	2,273.8	$	2,590.6	$	4,915.0	$	2,172.7	$	2,742.3
Trade names	363.4		279.5		83.9		366.8		272.9		93.9
Other	637.7		390.3		247.4		641.6		376.3		265.3
Total finite-lived	$	5,865.5	$	2,943.6	2,921.9		$	5,923.4	$	2,821.9	3,101.5
Indefinite-lived					92.3						92.3
Total					$	3,014.2					$	3,193.8

1.As of June 30, 2026 and December 31, 2025, accumulated impairment losses on Customer relationships were $65.9 million and on Other were $40.5 million, totaling $106.4 million.